Philips to Suspend Production of External Defibrillators at US Facilities
11 Outubro 2017 - 3:08AM
Dow Jones News
By Adria Calatayud
Koninklijke Philips NV (PHIA.AE) said on Wednesday that it has
agreed with the U.S. Department of Justice to suspend production
and distribution of external defibrillators manufactured at its
facilities in Andover, Massachusetts, and Bothell, Washington.
The Dutch health-technology company said it anticipates the
suspension to have an impact of approximately 20 million euros
($23.6 million) on its earnings before interest, taxes and
amortization in the fourth quarter of 2017 and of EUR60 million in
2018. Combined sales of the affected defibrillator product lines
were around EUR35 million per quarter in 2016, the company
added.
Philips said the agreement was reached by its subsidiary Philips
North America LLC with the Department of Justice, representing the
Food and Drug Administration, and the suspension came about
following inspections in and before 2015. The suspension will
remain in place until the FDA certifies Philips' facilities comply
with regulations, Philips added.
The company also said that its defibrillators currently in use
shouldn't be taken out of service as it has no reason to believe
they pose a risk to patients.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 11, 2017 01:53 ET (05:53 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Koninklijke Philips NV (EU:PHIA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
